174 related articles for article (PubMed ID: 30974033)
1. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
Eghbali M; Alaei-Shahmiri F; Hashemi-Madani N; Emami Z; Mostafavi L; Malek M; Khamseh ME
Adv Ther; 2024 Feb; 41(2):826-836. PubMed ID: 38172377
[TBL] [Abstract][Full Text] [Related]
4. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
Jiao BL; Zhao J; Wang B; Liu BY; Wu T
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3073-3084. PubMed ID: 38708466
[TBL] [Abstract][Full Text] [Related]
6. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.
Del Olmo-Garcia MI; Merino-Torres JF
J Diabetes Res; 2018; 2018():4020492. PubMed ID: 29805980
[TBL] [Abstract][Full Text] [Related]
8. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.
Gluud LL; Knop FK; Vilsbøll T
BMJ Open; 2014 Dec; 4(12):e005325. PubMed ID: 25526792
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.
Adamou A; Barkas F; Milionis H; Ntaios G
Int J Stroke; 2024 May; ():17474930241253988. PubMed ID: 38676552
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.
Silverii GA; Marinelli C; Mannucci E; Rotella F
Diabetes Obes Metab; 2024 Jun; 26(6):2505-2508. PubMed ID: 38449004
[No Abstract] [Full Text] [Related]
11. The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.
Sheng L; Deng M; Li X; Wan H; Lei C; Prabahar K; Hernández-Wolters B; Kord-Varkaneh H
Diabetes Res Clin Pract; 2024 Apr; 210():111617. PubMed ID: 38490492
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.
Wu Z; Deng W; Ye Y; Xu J; Han D; Zheng Y; Zheng Q
Front Endocrinol (Lausanne); 2024; 15():1378291. PubMed ID: 38868747
[TBL] [Abstract][Full Text] [Related]
13. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti GB; Ho AM; Silva LMD; Phelan R
Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
[TBL] [Abstract][Full Text] [Related]
14. A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
Goldenberg RM
Diabetes Obes Metab; 2024 Jul; 26(7):2997-2999. PubMed ID: 38576082
[No Abstract] [Full Text] [Related]
15. Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.
Xia W; Yu H; Wen P
Int Wound J; 2024 Apr; 21(4):e14841. PubMed ID: 38512120
[TBL] [Abstract][Full Text] [Related]
16. Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.
Liang Y; Doré V; Rowe CC; Krishnadas N
J Alzheimers Dis Rep; 2024; 8(1):777-789. PubMed ID: 38746639
[TBL] [Abstract][Full Text] [Related]
17. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
Ayoub M; Faris C; Juranovic T; Chela H; Daglilar E
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730578
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Effects of Anti-diabetic Drugs in the Treatment of Patients with Diabetes and Glaucoma or at High Risk for Glaucoma.
Weisser B; Erb C
Klin Monbl Augenheilkd; 2024 Mar; 241(3):302-307. PubMed ID: 37336238
[TBL] [Abstract][Full Text] [Related]
19. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
